The evaluation of endpoint variability and implications for study statistical power and sample size in conscious instrumented dogs

被引:3
作者
Chiang, Alan Y. [1 ]
Guth, Brian D. [2 ,9 ]
Pugsley, Michael K. [3 ]
Foley, C. Michael [4 ]
Doyle, Jennifer M. [5 ]
Engwall, Michael J. [6 ]
Koerner, John E. [7 ]
Parish, Stanley T. [8 ]
Sarazan, R. Dustan
机构
[1] Eli Lilly & Co, Indianapolis, IN 46285 USA
[2] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany
[3] Purdue Pharma LP, Stamford, CT USA
[4] AbbVie, Abbott Pk, IL USA
[5] Data Sci Int, St Paul, MN USA
[6] Amgen Inc, Thousand Oaks, CA USA
[7] US FDA, Washington, DC 20204 USA
[8] HESI, Washington, DC USA
[9] North West Univ, Preclin Drug Dev Platform, Potchefstroom, South Africa
关键词
Double Latin Square design; Myocardial; Left ventricular dP/dt; Variability; Test sensitivity; Heart rate; Time interval average; Super-interval; Statistical power; DRUG-INDUCED CHANGES; SAFETY ASSESSMENT; REQUIREMENTS; BJP;
D O I
10.1016/j.vascn.2018.02.009
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: The sensitivity of a given test to detect a treatment-induced effect in a variable of interest is intrinsically related to the variability of that variable observed without treatment and the number of observations made in the study (i.e. number of animals). To evaluate test sensitivity to detect drug-induced changes in myocardial contractility using the variable LVdP/dt(max), a HESI-supported consortium designed and conducted studies in chronically instrumented, conscious dogs using telemetry. This paper evaluated the inherent variability of the primary endpoint, LVdP/dt(max), over time in individual animals as well as the variability between animals for a given laboratory. An approach is described to evaluate test system variability and thereby test sensitivity which may be used to support the selection of the number of animals for a given study, based on the desired test sensitivity. Methods: A double 4 x 4 Latin square study design where eight animals each received a vehicle control and three dose levels of a test compound was conducted at six independent laboratories. LVdP/dt(max) was assessed via implanted telemetry systems in Beagle dogs (N = 8) using the same protocol and each of the six laboratories conducted between two and four studies. Vehicle data from each study was used to evaluate the between-animal and within-animal variability in different time averaging windows. Simulations were conducted to evaluate statistical power and type I error for LVdP/dt(max) based on the estimated variability and assumed treatment effects in hourly-interval, bi-hourly interval, or drug-specific super interval. Results: We observe that the within-animal variability can be reduced by as much as 30% through the use of a larger time averaging window. Laboratory is a significant source of animal-to-animal variability as between-animal variability is laboratory-dependent and is less impacted by the use of different time averaging windows. The statistical power analysis shows that with N = 8, the double Latin square design has over 90% power to detect a minimal time profile with a maximum change of up to 15% or approximately 450 mm Hg/s in LVdP/dt(max). With N = 4, the single Latin square design has over 80% power to detect a minimal time profile with a maximum change of up to 20% or approximately 600 mm Hg/s in LVdP/dt(max). Discussion: We describe a statistical procedure to quantitatively evaluate the acute cardiac effects from studies conducted across six sites and objectively examine the variability and sensitivity that were difficult or impossible to calculate consistently based on previous works. Although this report focuses on the evaluation on LVdP/dt(max), this approach is appropriate for other variables such as heart rate, arterial blood pressure, or variables derived from the ECG.
引用
收藏
页码:43 / 51
页数:9
相关论文
共 14 条
[1]  
[Anonymous], 2006, RESPONSE SURFACES MI
[2]   Incorporating Biomarkers Into the Analysis of Preclinical Cardiovascular Safety Studies [J].
Chiang, Alan Y. ;
Wang, Ming-Dauh .
STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2015, 7 (01) :66-75
[3]  
Chiang Alan Y., 2004, Journal of Pharmacological and Toxicological Methods, V50, P121, DOI 10.1016/j.vascn.2004.03.009
[4]   Experimental design and analysis and their reporting: new guidance for publication in BJP [J].
Curtis, Michael J. ;
Bond, Richard A. ;
Spina, Domenico ;
Ahluwalia, Amrita ;
Alexander, Stephen P. A. ;
Giembycz, Mark A. ;
Gilchrist, Annette ;
Hoyer, Daniel ;
Insel, Paul A. ;
Izzo, Angelo A. ;
Lawrence, Andrew J. ;
MacEwan, David J. ;
Moon, Lawrence D. F. ;
Wonnacott, Sue ;
Weston, Arthur H. ;
McGrath, John C. .
BRITISH JOURNAL OF PHARMACOLOGY, 2015, 172 (14) :3461-3471
[5]   The evaluation of drug-induced changes in cardiac inotropy in dogs: Results from a HESI-sponsored consortium [J].
Guth, Brian D. ;
Chiang, Alan Y. ;
Doyle, Jennifer ;
Engwall, Michael J. ;
Guillon, Jean-Michel ;
Hoffmann, Peter ;
Koerner, John ;
Mittelstadt, Scott ;
Ottinger, Sean ;
Pierson, Jennifer Beck ;
Pugsley, Michael K. ;
Rossman, Eric I. ;
Walisser, Jacqueline ;
Sarazan, Dustan .
JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS, 2015, 75 :70-90
[6]   The analysis of repeated measures designs: A review [J].
Keselman, HJ ;
Algina, J ;
Kowalchuk, RK .
BRITISH JOURNAL OF MATHEMATICAL & STATISTICAL PSYCHOLOGY, 2001, 54 :1-20
[7]  
Littell RC, 2000, STAT MED, V19, P1793, DOI 10.1002/1097-0258(20000715)19:13<1793::AID-SIM482>3.0.CO
[8]  
2-Q
[9]   BJP is changing its requirements for scientific papers to increase transparency [J].
McGrath, J. C. ;
Curtis, M. J. .
BRITISH JOURNAL OF PHARMACOLOGY, 2015, 172 (11) :2671-2674
[10]   An evaluation of the utility of LVdP/dt40, QA interval, LVdP/dtmin and Tau as indicators of drug-induced changes in contractility and lusitropy in dogs [J].
Pugsley, Michael K. ;
Guth, Brian ;
Chiang, Alan Y. ;
Doyle, Jennifer M. ;
Engwall, Michael ;
Guillon, Jean-Michel ;
Hoffmann, Peter K. ;
Koerner, John E. ;
Mittelstadt, Scott W. ;
Pierson, Jennifer Beck ;
Rossman, Eric I. ;
Sarazan, Dustan R. ;
Parish, Stanley T. .
JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS, 2017, 85 :1-21